|
1
|
Yerby MS: Clinical care of pregnant women
with epilepsy: neural tube defects and folic acid supplementation.
Epilepsia. 44:(Suppl 3). 33–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rogawski MA and Löscher W: The
neurobiology of antiepileptic drugs for the treatment of
nonepileptic conditions. Nat Med. 10:685–692. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmidt D, Canger R, Avanzini G, Battino
D, Cusi C, Beck-Mannagetta G, Koch S, Rating D and Janz D: Change
of seizure frequency in pregnant epileptic women. J Neurol
Neurosurg Psychiatry. 46:751–755. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crawford P: Best practice guidelines for
the management of women with epilepsy. Epilepsia. 46:(Suppl 9).
117–124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meador KJ, Baker G, Cohen MJ, Gaily E and
Westerveld M: Cognitive/behavioral teratogenetic effects of
antiepileptic drugs. Epilepsy Behav. 11:292–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adab N, Kini U, Vinten J, Ayres J, Baker
G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, et al: The
longer term outcome of children born to mothers with epilepsy. J
Neurol Neurosurg Psychiatry. 75:1575–1583. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meador K, Reynolds MW, Crean S, Fahrbach K
and Probst C: Pregnancy outcomes in women with epilepsy: a
systematic review and meta-analysis of published pregnancy
registries and cohorts. Epilepsy Res. 81:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jentink J, Loane MA, Dolk H, Barisic I,
Garne E, Morris JK and de Jong-van den Berg LT: EUROCAT
Antiepileptic Study Working Group: Valproic acid monotherapy in
pregnancy and major congenital malformations. N Engl J Med.
362:2185–2193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morrow J, Russell A, Guthrie E, Parsons L,
Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ and Craig
J: Malformation risks of antiepileptic drugs in pregnancy: a
prospective study from the UK Epilepsy and Pregnancy Register. J
Neurol Neurosurg Psychiatry. 77:193–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samrén EB, van Duijn CM, Koch S, Hiilesmaa
VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E,
Granström ML, et al: Maternal use of antiepileptic drugs and the
risk of major congenital malformations: a joint European
prospective study of human teratogenesis associated with maternal
epilepsy. Epilepsia. 38:981–990. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vinten J, Adab N, Kini U, Gorry J, Gregg J
and Baker GA: Liverpool and Manchester Neurodevelopment Study
Group: Neuropsychological effects of exposure to anticonvulsant
medication in utero. Neurology. 64:949–954. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas SV, Indrani L, Devi GC, Jacob S,
Beegum J, Jacob PP, Kesavadas K, Radhakrishnan K and Sarma PS:
Pregnancy in women with epilepsy: preliminary results of Kerala
registry of epilepsy and pregnancy. Neurol India. 49:60–66.
2001.PubMed/NCBI
|
|
13
|
Baker GA, Bromley RL, Briggs M, Cheyne CP,
Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G,
et al: Liverpool and Manchester Neurodevelopment Group: IQ at 6
years after in utero exposure to antiepileptic drugs: a controlled
cohort study. Neurology. 84:382–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McVearry KM, Gaillard WD, VanMeter J and
Meador KJ: A prospective study of cognitive fluency and originality
in children exposed in utero to carbamazepine, lamotrigine, or
valproate monotherapy. Epilepsy Behav. 16:609–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaily E, Kantola-Sorsa E, Hiilesmaa V,
Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E and
Granstrom ML: Normal intelligence in children with prenatal
exposure to carbamazepine. Neurology. 62:28–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hill DS, Wlodarczyk BJ, Palacios AM and
Finnell RH: Teratogenic effects of antiepileptic drugs. Expert Rev
Neurother. 10:943–959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rogawski MA and Löscher W: The
neurobiology of antiepileptic drugs. Nat Rev Neurosci. 5:553–564.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Walker BE and Patterson A: Induction of
cleft palate in mice by tranquilizers and barbiturates. Teratology.
10:159–163. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ornoy A: Neuroteratogens in man: an
overview with special emphasis on the teratogenicity of
antiepileptic drugs in pregnancy. Reprod Toxicol. 22:214–226. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mantovani A and Calamandrei G: Delayed
developmental effects following prenatal exposure to drugs. Curr
Pharm Des. 7:859–880. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wlodarczyk BJ, Palacios AM, George TM and
Finnell RH: Antiepileptic drugs and pregnancy outcomes. Am J Med
Genet A. 158A:2071–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bruni J and Wilder BJ: Valproic acid.
Review of a new antiepileptic drug. Arch Neurol. 36:393–398. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herrmann K: Effects of the anticonvulsant
drug valproic acid and related substances on the early development
of the zebrafish (Brachydanio rerio). Toxicol In Vitro. 7:41–54.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rao S, Rajesh KR and Joseph T: Effect of
antiepileptic drugs valproic acid, carbamazepine and ethosuccimide
on exploratory behaviour in mice. Indian J Exp Biol. 29:127–130.
1991.PubMed/NCBI
|
|
25
|
Eyal S, Lamb JG, Smith-Yockman M, Yagen B,
Fibach E, Altschuler Y, White HS and Bialer M: The antiepileptic
and anticancer agent, valproic acid, induces P-glycoprotein in
human tumour cell lines and in rat liver. Br J Pharmacol.
149:250–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wlodarczyk B, Biernacki B and Minta M:
Teratogenic action of antiepileptic drug: 2-Propylpentanoic
acid-effects on rat and hamster embryos cultured in vitro. Ginekol
Pol. 72:955–960. 2001.PubMed/NCBI
|
|
27
|
Faiella A, Wernig M, Consalez GG, Hostick
U, Hofmann C, Hustert E, Boncinelli E, Balling R and Nadeau JH: A
mouse model for valproate teratogenicity: parental effects,
homeotic transformations, and altered HOX expression. Hum Mol
Genet. 9:227–236. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DiLiberti JH, Farndon PA, Dennis NR and
Curry CJ: The fetal valproate syndrome. Am J Med Genet. 19:473–481.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ornoy A: Valproic acid in pregnancy: how
much are we endangering the embryo and fetus? Reprod Toxicol.
28:1–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diav-Citrin O, Shechtman S, Arnon J and
Ornoy A: Is carbamazepine teratogenic? A prospective controlled
study of 210 pregnancies. Neurology. 57:321–324. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harding JJ and Timko JV: The use of
psychotropic medications during pregnancy and lactation. The
Foundation for The Global Library of Women's Medicine; Carlisle:
1999
|
|
32
|
Holmes LB, Harvey EA, Coull BA, Huntington
KB, Khoshbin S, Hayes AM and Ryan LM: The teratogenicity of
anticonvulsant drugs. N Engl J Med. 344:1132–1138. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cunnington M and Tennis P: International
Lamotrigine Pregnancy Registry Scientific Advisory Committee:
Lamotrigine and the risk of malformations in pregnancy. Neurology.
64:955–960. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tennis P and Eldridge RR: International
Lamotrigine Pregnancy Registry Scientific Advisory Committee:
Preliminary results on pregnancy outcomes in women using
lamotrigine. Epilepsia. 43:1161–1167. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allen RW Jr, Ogden B, Bentley FL and Jung
AL: Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic
disease in a neonate. JAMA. 244:1464–1465. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Adams J, Vorhees CV and Middaugh LD:
Developmental neurotoxicity of anticonvulsants: human and animal
evidence on phenytoin. Neurotoxicol Teratol. 12:203–214. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hunt S, Russell A, Smithson WH, Parsons L,
Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J and Craig J:
UK Epilepsy and Pregnancy Register: Topiramate in pregnancy:
preliminary experience from the UK Epilepsy and Pregnancy Register.
Neurology. 71:272–276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lindhout D and Omtzigt JG: Teratogenic
effects of antiepileptic drugs: implications for the management of
epilepsy in women of childbearing age. Epilepsia. 35:(Suppl 4).
S19–S28. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tennis P, Chan KA, Curkendall SM, Li DK,
Mines D, Peterson C, Andrews EB, Calingaert B, Chen HY, Deshpande
G, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ
and Esposito DB: Topiramate use during pregnancy and major
congenital malformations in multiple populations. Birth Defects Res
A Clin Mol Teratol. 103:269–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Green MW, Seeger JD, Peterson C and
Bhattacharyya A: Utilization of topiramate during pregnancy and
risk of birth defects. Headache. 52:1070–1084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lombardo SA, Leanza G, Meli C, Lombardo
ME, Mazzone L, Vincenti I and Cioni M: Maternal exposure to the
antiepileptic drug vigabatrin affects postnatal development in the
rat. Neurol Sci. 26:89–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kroes HY, Reefhuis J and Cornel MC: Is
there an association between maternal carbamazepine use during
pregnancy and eye malformations in the child? Epilepsia.
43:929–931. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Turanli G, Celebi A, Yalnizoglu D, Topcu
M, Topaloglu H, Banu A and Aysun S: Vigabatrin in pediatric
patients with refractory epilepsy. Turk J Pediatr. 48:25–30.
2006.PubMed/NCBI
|
